Inflammation is often described as the body's alarm system, rushing immune cells to an area where there is an infection or injury. But just as important as switching inflammation on is knowing when to switch it off. Now, scientists have uncovered a previously underexplored mechanism that appears to help the body do exactly that. Researchers from University College London and collaborating institutions have identified a group of fat-derived molecules called epoxy-oxylipins that appear to act as a natural brake on inflammation. Their findings, published in Nature Communications, offer new clues about how the immune system moves from an active inflammatory response towards recovery. The body's built-in braking system Inflammation itself is not necessarily harmful. It is a crucial part of the immune response, helping the body deal with infections, injuries and damaged tissue. Problems can arise when the inflammatory response persists after the original threat has passed. The researchers focused on a type of white blood cell called an intermediate monocyte. These cells can have useful roles during an immune response, but their prolonged expansion has also been associated with chronic inflammatory conditions. The study suggests that epoxy-oxylipins help prevent these cells from accumulating excessively, allowing the inflammatory response to move towards resolution. One molecule stood out in particular: 12,13-EpOME. Researchers found that it appears to interfere with a signalling pathway involving a protein called p38 MAPK. This pathway helps drive the transition of conventional monocytes into the intermediate form. By suppressing this signal, 12,13-EpOME reduced the expansion of intermediate monocytes during inflammation. To investigate the process in humans, the researchers created a controlled, temporary inflammatory response by injecting volunteers with UV-killed E. coli. Because the bacteria had been killed, the procedure did not cause an infection, but it produced a measurable local inflammatory reaction. The team then used GSK2256294, a drug that inhibits an enzyme called soluble epoxide hydrolase, or sEH. This enzyme normally breaks down certain epoxy-oxylipins. Blocking it allowed some of these molecules, including 12,13-EpOME, to remain at higher levels. The intervention was associated with fewer intermediate monocytes and faster resolution of pain. However, there is an important detail that prevents the findings from being overstated: the treatment did not significantly change visible signs of inflammation such as redness, swelling or heat. That distinction matters. The researchers were not demonstrating that inflammation can simply be switched off like a light. Instead, they identified a biological pathway that appears to influence how the immune response settles down. The study also found that the drug did not significantly alter several common inflammatory cytokines and chemokines, suggesting that the mechanism may work differently from broad immune suppression. Now the next question would be, could this lead to new treatments? That is where the discovery becomes particularly interesting. Many current treatments for inflammatory and autoimmune diseases work by suppressing immune activity. While this can reduce harmful inflammation, excessive immune suppression can also interfere with the body's normal defence mechanisms. A treatment that strengthens the body's own inflammation-resolution machinery could potentially offer a more targeted approach. The researchers believe the pathway could eventually be investigated for conditions involving persistent inflammation, including diseases such as rheumatoid arthritis. However, that possibility remains in the future. The human experiment involved a small group of healthy volunteers and an experimentally induced short-term inflammatory response. It does not yet show that sEH inhibitors can treat chronic inflammatory diseases in patients. Still, the discovery changes the way scientists think about inflammation. The immune system does not simply have an accelerator; it also has biological mechanisms designed to bring the response back under control. And this newly mapped pathway may be one of those hidden brakes. Simran covers books that start conversations, beauty insights, fashion moods, and stories that make people feel something. Off duty? You’ll find her c... View More